CANNABIDIOL-TYPE CANNABINOID COMPOUND
The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, cannabidiol-C4 (CBD-C4), is a naturally occurring cannabinoid that can be found in minor quantities in the cannabis plant. Furthermore, the cannabinoid can be produced by synthetic means. Disclosed herein are data which demonstrate the efficacy of CBD-C4 in models of disease. In addition, a method for the production of CBD-C4 is described.
1 . Cannabidiol-C4 (CBD-C4) for use as a medicament.
2 . CBD-C4 for use according to claim 1 , wherein the CBD-C4 is in the form of a plant extract.
3 . CBD-C4 for use according to claim 2 , wherein the CBD-C4 is in the form of a highly purified plant extract.
4 . CBD-C4 for use according to claim 3 , wherein the CBD-C4 is comprises at least 80% (w/w) CBD-C4.
5 . CBD-C4 for use according to claim 3 , wherein the CBD-C4 is comprises at least 95% (w/w) CBD-C4.
6 . CBD-C4 for use according to claim 1 , wherein the CBD-C4 is in the form of a synthetic compound.
7 . CBD-C4 for use according to any of the preceding claims, wherein the dose of CBD-C4 is greater than 100 mg/kg/day.
8 . CBD-C4 for use according to any of the preceding claims, wherein the dose of CBD-C4 is less than 100 mg/kg/day.
9 . A composition for use as a medicament comprising cannabidiol-C4 (CBD-C4) and one or more pharmaceutically acceptable excipients.
10 . Cannabidiol-C4 (CBD-C4) for use in the treatment of epilepsy.
11 . Cannabidiol-C4 (CBD-C4) for use in the treatment of schizophrenia.
12 . A process for the preparation of cannabidiol-C4 (CBD-C4).